Cardiovascular diseases are the leading cause of mortality and morbidity worldwide.1 Unfortunately, in many patients cardiac arrest is the first manifestation of cardiac disease.2 In spite of great improvements in health care, prognosis after cardiac arrest remains dismal and over the past 30 years there have been no dramatic changes in survival rates.3 Several factors have been shown to influence long-term prognosis of cardiac arrest patients: an initial shockable rhythm (ventricular tachycardia or ventricular fibrillation), cardiopulmonary resuscitation (CPR) initiated by bystanders, early defibrillation, and introduction of intensive treatment are associated with more favorable outcome.4,5 It thus seems intuitive that, due to easier and faster access to medical support and treatment, patients who experience in-hospital cardiac arrest (IHCA) will have better prognosis than those with out-of-hospital cardiac arrest (OHCA). Various biomarkers have been extensively studied in order to develop protocols for risk assessment in this group of patients. The aim of this study was to analyze the prognostic implications of N-terminal pro-B-type natriuretic peptide (NT-proBNP) measured on admission and serial cardiac troponin I determination in patients with IHCA.

Out of 9877 patients hospitalized during the study enrollment period in the intensive cardiac care unit, 106 were included in the study (61 male, age 71.4±12.6 years) in accordance with the inclusion and exclusion criteria. Many patients had a history of major adverse cardiac events: 34 (32.1%) had a history of myocardial infarction and 13 (12.3%) of stroke (Table 1). In the majority of cases (87.7%) the primary diagnosis on admission was acute coronary syndrome; other primary diagnoses included cardiac arrhythmias (5.7%) and exacerbation of heart failure (6.6%). Mean systolic and diastolic blood pressure on admission were 97.8±35.3 and 57.7±22.8 mmHg, respectively. Median serum troponin I concentration on admission was 0.5 ng/ml (25–75% IQR, 0.1–5.3), the second measurement (6–9 hours after admission) was 24.0 ng/ml (25–75% IQR, 3.5–80.4), and the third (12–24 hours after admission) was 49.8 ng/ml (25–75% IQR, 8.3–80.0). Total all-cause 30-day mortality was 60.4%.

After dividing patients into survivors and non-survivors of the first 30-day period, we saw differences in baseline characteristics, clinical profile and outcome. There were 64 patients in the non-survivor group (60.4%) and 42 (39.6%) in the survivor group. Deceased patients were older (73.7±11.9 vs. 67.8±13.0 years; p=0.01) than survivors. They also had lower systolic (89.4±37.0 vs. 115.0±24.0 mmHg; p=0.0001) and diastolic (53.6±24.8 vs. 66.1±15.0 mmHg; p=0.008) blood pressure on admission. There were no differences between the groups concerning gender, body mass index, or history of hypertension, diabetes, myocardial infarction, or prior cardiac arrest (p>0.05). Concerning circumstances of cardiac arrest and applied treatment, significant differences were noted only in the prevalence of shockable initial rhythm (ventricular fibrillation/ventricular tachycardia), which was present less often in the deceased than in survivors (28.1% vs. 54.8%; p=0.01) (Table 2). The most common cause of cardiac arrest in this group was myocardial infarction (87 patients, 82.1%). Cardiac arrest was caused by heart failure in five patients (4.7%), electrolyte abnormalities in seven (6.6%), pulmonary embolism in two (1.9%), renal failure in two (1.9%), respiratory failure in two (1.9%), and aortic dissection in one (0.9%).

In admission laboratory results the median serum NT-proBNP level was higher (9590.0 [25–75% IQR, 5640.0–26450.0] vs. 3190.0 [25–75% IQR, 973.8–5362.5] pg/ml; p=0.02) and median estimated glomerular filtration rate (eGFR) was lower (36.0 [25–75% IQR, 25.0–49.5] vs. 55.5 [25–75% IQR, 41.5–60.0] ml/min/1.73 m2; p=0.001) in deceased patients compared to survivors. There were no statistical differences between the groups in the first two measurements of troponin I concentration (median 0.6 vs. 0.5 ng/ml; p=0.97, and 37.1 vs. 17.5 ng/ml; p=0.37, respectively). However, the third measurement showed an almost four-fold higher mean troponin I concentration in the deceased than the survivor group (98.2 [25–75% IQR, 76.4–175.8] vs. 18.7 [25–75% IQR, 5.2–50.6]; p=0.009) (Figure 1). The area under the ROC curve to predict 30-day mortality was 0.778 (95% CI, 0.57–0.92) for NT-proBNP concentration, and 0.885 (95% CI, 0.66–0.98) for the third troponin I measurement. The ROC curves for NT-proBNP and the third troponin I measurement are depicted in Figures 2A and 2B, respectively. Comparison of the two ROC curves showed no statistical difference (p>0.05).

Figure 1.

Comparison of mean troponin I concentrations in different measurements between survivors and non-survivors.

(0,11MB).

Figure 2.

Receiver operating characteristic curves for N-terminal pro-B-type natriuretic peptide (A) and third measurement of troponin I (B).

(0,12MB).

Of the 30-day survivors, three additional patients died during prolonged hospitalization, and 39 (36.8%) were discharged alive. Mean hospital stay was 31.1±37.7 days.

The management of patients after cardiac arrest is still challenging in spite of constant advances in medicine. The majority of cardiac arrests are associated with conditions involving the heart muscle itself. Coronary artery abnormalities, myocarditis, and hypertrophic cardiomyopathy account for about 63% of cases of cardiac arrest.8 But not all cardiac arrests are actually of cardiac origin. It has been shown that in IHCA patients the immediate cause was cardiac in 39% of cases.9 Non-cardiac origins of cardiac arrest include hemorrhage, intracranial processes, lung disease, malignancy, intoxication, trauma, and suffocation. In this group survival to discharge is even lower than in patients with cardiac etiology.10 Whether the cause is cardiac or non-cardiac, what is important is the reversibility of the process. There is also little known about the long-term outcomes of survivors. There are some data on in-hospital and short-term mortality, but hardly any studies go beyond a one-year period.11 We present data from almost five years of observation of patients in a cardiac intensive care unit, so this trend is not surprising. However, this trend is constant even if data are collected from all emergency department patients.

Regardless of the cause, mortality rates and neurological prognosis remain poor.12 Development of optimal strategies for management of cardiac arrest patients is both important and extremely difficult, due to a variety of factors. During cardiac arrest saving human life is the priority, pushing scientific research into the background; large prospective studies to validate different CPR strategies are almost impossible to carry out due to ethical and other considerations.13 Furthermore, studies aiming to describe appropriate behavior models are required, but are rare.14

Applying even strictly specified CPR and other management techniques depends on initial diagnosis and appropriately categorizing the patient's status. As mentioned above, time is crucial at every step of the process, from initial diagnosis to administration of treatment, which is especially important in emergency departments.4,5 There is still a lack of simple, proven tools, scales or biomarkers which can predict short- and/or long-term survival and neurological outcome of cardiac arrest patients.15 It is still necessary to depend on clinical examination along with experience to decide on appropriate treatment. In this situation it is helpful to realize that cardiac arrest patients are a heterogeneous group whose initial characteristics influence outcome. Various biomarkers have been studied in the settings of cardiac arrest, but as the causes of cardiac arrest, primary myocardial infarction, may differ between patients, the same goes for the biomarker utility.16,17

In our study we examined only patients with cardiac arrest within 12 hours of admission. This specific criterion was applied to rule out patients with exacerbation of chronic critical disease, and to include the clinical characteristics of patients most often encountered in an emergency department. There were no significant differences in the baseline characteristics of the two groups, except for older age in the deceased group. Laboratory results showed that eGFR was significantly lower in deceased patients, which shows that they had worse renal function. Renal disease is known to increase the risk of cardiovascular disease; for example chronic kidney disease is now considered a coronary heart disease risk equivalent, placing patients at high risk for coronary events. Cardiac arrest risk is higher with every level of kidney disease, which is estimated to be a cause of about 60% of cardiovascular deaths.18

Another important clinical finding in our study were higher NT-proBNP levels in deceased patients. Baseline NT-proBNP concentration was previously shown to be predictive of sudden cardiac death in the general population.19 Another factor that our study showed to be predictive of outcome was troponin I level on the third measurement. Many patients have elevated troponin concentrations after cardiac arrest irrespective of its etiology.20 Nevertheless, elevated troponin concentration is predictive of myocardial damage, size of coronary artery thrombus, and death, as well as other acute conditions in this group of patients.21,22 In our study first measurements of troponin I concentration were similar in non-survivors and survivors. Then, in survivors there was a slight elevation in the second measurement, and a slow decrease in the third. However in non-survivors there was a constant rise through the second and third measurements (Figure 1), which may show that myocardial damage expanded rather than decreased.

Some studies show that prognosis in patients with IHCA is worse than in those experiencing OHCA. It has been shown that in-hospital presentation of life-threatening ventricular arrhythmias is associated with worse prognosis than out-of-hospital.22 The authors concluded that this may be due to greater burdens of concomitant disease in the in-hospital group. These findings may also apply to our study, but other possible explanations may include greater disease severity causing cardiac arrest. We may suspect that the overall clinical state of IHCA patients is generally worse than in OHCA. First of all, their cardiac arrest took place when they were already admitted and were thus under medical supervision and receiving pharmacological and other treatment. Although all the IHCA took place in the presence of medical personnel, and in the majority there was no delay in administering CPR, it was still associated with poor prognosis in our study, as in others.23,24 A shockable initial rhythm, defined as ventricular fibrillation or ventricular tachycardia as the first cardiac arrest rhythm, is associated with better outcome. As may be predicted, a shockable initial rhythm was more often present in survivors than the deceased group. There were differences in management concerning the use of an intra-aortic balloon pump (IABP), which was more often applied in IHCA patients. The small number of participants in our study does not provide sufficient data to draw conclusions about the efficacy of IABP treatment. Nevertheless its efficacy in improving survival in, for example, cardiogenic shock has recently been questioned.25 In our study different rates of IABP use are rather a reflection of the worse clinical status of IHCA patients.

The present study has certain limitations. Firstly, the patients enrolled were hospitalized only in the intensive care unit of a cardiology department, and so the results presented may not be applicable to the whole population of IHCA patients. Secondly, for more accurate results the study population should have been larger. We are also unable to provide an explanation why NT-proBNP and troponin I levels were elevated in the study patients. It is probably due to many reasons, including CPR and in many cases acute coronary syndrome. The relationship of troponin levels and echocardiographic findings in the present study also cannot be objectively analyzed, because many patients had a previous history of myocardial infarction or coronary artery disease, therefore without previous medical records we are unable to confirm whether impaired contractility or reduced ejection fraction were related to the current hospitalization.

Patients with in-hospital cardiac arrest have poor short-term prognosis; the short-term survival rate of patients after IHCA within 12 hours of hospitalization is 39.6%. Deceased patients have higher NT-proBNP levels on admission, along with higher troponin I concentrations on the third measurement. The above-mentioned biomarkers are useful in predicting 30-day mortality in IHCA patients, and may be valuable in planning treatment strategies in this group of patients.

The authors have no conflicts of interest to declare.